At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 6 enrolled
Drug / intervention
Minocyclinedrug
Likely dose
Minocycline 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study for the Evaluation of Minocycline as a Microglia Inhibitor in the Treatment of Diabetic Macular Edema
In Brief
A Phase 2 clinical trial evaluating Minocycline for Diabetic Macular Edema. Completed, enrolled 6 participants across 1 site.
Detailed Summary
The objective of this study is to investigate the safety and efficacy of minocycline as a microglia inhibitor in individuals with diabetic macular edema (DME).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Macular Edema
CountriesUnited States
CollaboratorsThe Emmes Company, LLC
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2010
First PostedMay 2010
Primary CompletionAug 2011
Study CompletionFeb 2013
TodayJul 2026
First PostedMay 11, 2010
Enrollment StartApr 1, 2010
Primary CompletionAug 1, 2011
Study CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 16.1 years ago
Interventions
Minocyclinedrug
Participants take 100 mg minocycline pills twice daily for 24 months.